Palantir Faces New Regulatory Pressure in UK Over NHS Contract

Palantir Technologies (PLTR) is facing renewed political pressure in the United Kingdom over its £330 million contract to run the National Health Service's (NHS) federated data platform. According to a report from TheStreet, the pressure comes at a sensitive time for the company as it seeks to expand its footprint in government markets.

Details of the Regulatory Action

The contract awarded to Palantir aims to connect data from hospitals and clinics across England via a unified platform, facilitating analysis and research. However, critics argue that the deal gives the U.S. company significant access to sensitive health data, raising concerns about privacy and sovereignty.

Company's Position

Palantir defends the contract, stating that the platform is designed with the highest security and privacy standards, and that data remains under NHS control. The company also highlights that the contract helps improve healthcare through more effective data analysis.

Context and Precedents

This is not the first time Palantir has faced criticism in the UK. In 2021, its collaboration with the Ministry of Defense sparked similar controversy. The company also faces comparable challenges in other countries, including Germany and Norway.

Potential Financial Impact

If pressure escalates, Palantir may encounter difficulties in renewing the contract or securing new government deals in the UK. However, the current contract remains in effect, and no regulatory body has announced an official investigation yet.